Oligonucleotide Aptamer-Drug Conjugates for Targeted Therapy of Acute Myeloid Leukemia

Biomaterials - United Kingdom
doi 10.1016/j.biomaterials.2015.07.025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Targeted Therapy in Acute Myeloid Leukemia: Aim With Caution

International Journal of Hematologic Oncology
OncologyHematologyPharmacology
2012English

Therapy of Acute Myeloid Leukemia

2012English

Cell-Selective Oligonucleotide STAT3 Inhibitor for Immunotherapy of Human Acute Myeloid Leukemia

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Drug Repurposing for the Treatment of Acute Myeloid Leukemia

Frontiers in Medicine
Medicine
2017English

“Epigenetic” Modification as Therapy for Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2017English

Therapy-Related Myelodysplasia and Acute Myeloid Leukemia

Seminars in Oncology
OncologyHematology
2013English

Acute Myeloid Leukemia Stem Cells and CD33-targeted Immunotherapy

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Triplex-Forming Oligonucleotide-Orthophenanthroline Conjugates for Efficient Targeted Genome Modification

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

SHIP1 Is Targeted by miR-155 in Acute Myeloid Leukemia

Oncology Reports
MedicineCancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy